Optimization and Clinical Assessment of a Radioreceptor Assay for Thyrotropin-Binding Inhibitor Immunoglobulins
- 1 January 1987
- journal article
- research article
- Published by Japan Endocrine Society in Endocrinologia Japonica
- Vol. 34 (1) , 13-20
- https://doi.org/10.1507/endocrj1954.34.13
Abstract
We tried to improve the sensitivity of a radioreceptor assay for thyrotropin-binding inhibitor immunoglobulins (TBII) by modifying assay conditions. About a twofold increase in sensitivity without a loss of reproducibility was obtained by prolonging the incubation of the receptors with test serum from 15 to 120 min before the addition of 125I-labeled thyrotropin. In 20 untreated, 49 treated patients with Graves'' disease and 19 patients with euthyroid Graves'' disease, TBII activities obtained using 120 min preincubation were significantly higher than those obtained using 15 min preincubation (p < 0.005). No significant increase in TBII activities was observed in the presence of sera from patients with primary hypothyroidism (n = 17), simple goiter (n = 7), adenomatous goiter (n = 11), thyroid adenoma (n = 11) or cancer (n = 12). TBII were detectable in 15 (47%) or 32 triiodothyronine-nonsuppressible Graves'' patients who were receiving maintenance antithyroid drug therapy using 120 min preincubation, while they were positive in only 6 patients (19%) using 15 min preincubation. The assay using a longer preincubation period was found to be sensitive, specific and useful for diagnosis and follow-up of Graves'' disease.This publication has 14 references indexed in Scilit:
- Primary Myxedema with Thyrotrophin-Binding Inhibitor ImmunoglobulinsAnnals of Internal Medicine, 1985
- Prognostic value of thyrotrophin binding inhibiting immunoglobulins (TBII) in longterm antithyroid treatment, 131I therapy given in combination with carbimazole and in euthyroid ophthalmopathyActa Endocrinologica, 1981
- THYROTROPHIN BINDING INHIBITING IMMUNOGLOBULINS IN GRAVES' DISEASE BEFORE, DURING AND AFTER ANTITHYROID THERAPY, AND ITS RELATION TO LONG‐ACTING THYROID STIMULATORClinical Endocrinology, 1980
- Changes in Thyroid-Stimulating Antibody Activity in Graves' Disease Treated with Antithyroid Drug and Its Relationship to Relapse: A Prospective Study*Journal of Clinical Endocrinology & Metabolism, 1980
- The Natural History of Hyperthyroidism due to Graves' Disease in Remission: Sequential Studies of Pituitary-Thyroid Regulation and Various Serum Parameters*Journal of Clinical Endocrinology & Metabolism, 1979
- Correlation between Thyroid Stimulators and 3,5,3′-Triiodothyronine Suppressibility in Patients during Treatment for Hyperthyroidism with Thionamide Drugs:Comparison of Assays by Thyroid-Stimulating and Thyrotropin-Displacing Activities*Journal of Clinical Endocrinology & Metabolism, 1979
- Thyrotropin Displacement Activity of Serum Immunoglobulins from Patients with Graves’ Disease*Journal of Clinical Endocrinology & Metabolism, 1978
- Detection and Properties of TSH-Binding Inhibitor Immunoglobulins in Patients with Graves’ Disease and Hashimoto’s Thyroiditis*Journal of Clinical Endocrinology & Metabolism, 1978
- VALUE OF THYROID-STIMULATING-ANTIBODY DETERMINATIONS IN PREDICTING SHORT-TERM THYROTOXIC RELAPSE IN GRAVES' DISEASEThe Lancet, 1977
- THYROID-STIMULATING IMMUNOGLOBULINS IN OPHTHALMIC GRAVES'DISEASEClinical Endocrinology, 1977